Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study.
Deesje DoppenbergThomas F StoopSusan van DierenMatthew H G KatzQuisette P JanssenNaaz NasarLaura R PrakashRutger T TheijseChing-Wei D TzengAlice C WeiAmer H ZureikatBas Groot KoerkampMarc G H Besselinknull nullPublished in: Annals of surgical oncology (2024)
Serum CEA was elevated in one-third of patients with localized pancreatic adenocarcinoma having non-elevated CA19-9 at baseline. At both time of baseline and time of restaging, elevated serum CEA measured at baseline was the only predictor for (worse) OS. Therefore, serum CEA may be a useful tool for decision making at both initial staging and time of restaging in patients with non-elevated CA19-9.